Adagio Therapeutics Profit Margin

Adagio Therapeutics (ADGI) currently reports a profit margin of -183.9% as of June 2026. That compares with 82.13% in the prior-year period — down 323.9% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Adagio Therapeutics's profit margin history and peer comparisons.

Adagio Therapeutics's profit margin decreased from 82.13% to -183.9% — a 323.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adagio Therapeutics's profit margin of -183.9% is lower than the Healthcare sector average of 21.34%. That is roughly 962.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Adagio Therapeutics's current -183.9% should be judged against Healthcare norms (sector average: 21.34%) and against ADGI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -183.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Adagio Therapeutics, and consider following ADGI for alerts when major investors trade the stock.